# A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)

> **NCT06698042** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 67 (actual)

## Conditions studied

- Lung Cancer
- Non-Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** Pembrolizumab (+) Berahyaluronidase alfa
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT06698042
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-11-21
- **Primary completion:** 2026-03-12
- **Final completion:** 2030-02-11
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06698042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06698042, "A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06698042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*